search
Back to results

Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

Primary Purpose

Hand, Foot and Mouth Disease

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
EV71 vaccine
Sponsored by
Sinovac Biotech Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hand, Foot and Mouth Disease focused on measuring Inactivated Enterovirus Type 71 (EV71) Vaccine, Safety, Immunogenicity, Infant

Eligibility Criteria

6 Months - 35 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy volunteers aged 6-35 months old
  • Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study
  • Proven legal identity

Exclusion Criteria:

For subjects with any of the following conditions, vaccination should not be administrated:

  • History of hand foot and mouth disease
  • Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, pain, etc
  • Severe chronic diseases
  • Thrombocytopenia or hemorrhagic disease
  • Immunodeficiency disease or receipt of immunosuppressant treatment
  • Uncontrolled epilepsy or progressive neurological disorders(e.g. Guillain-Barre syndrome)
  • Acute disease or acute stage of chronic disease prior to the study entry
  • History of thyroidectomy, thyroid disease within 12 months prior to the study entry
  • Asplenia or functional asplenia
  • Axillary temperature >37.0 ℃
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the judgment of investigators

Exclusion Criteria of the Second Injection:

  • Subjects with any of the following conditions are forbidden to continue the 2nd dose of vaccination:

    1. Any serious adverse event that has a causal relationship with the investigated vaccine
    2. Severe allergic reactions or hypersensitivity after vaccination (including urticaria / rash appear within 30 minutes after vaccination
    3. Any confirmed or suspected autoimmune disease or immunodeficiency disease (e.g., HIV infection)
    4. Other reactions (including severe pain, severe swelling, severe activity limitation, persistent hyperthermia, severe headache or other systemic or local reactions)determined by the investigators
  • For subjects suffering from acute disease or acute stage of chronic disease , whether to continue vaccination depends on themselves
  • Subjects with the following conditions may receive vaccination in delayed time or withdraw from the study depending on the judgment of investigator

    1. Acute disease (moderate or severe disease with or without fever) in case of vaccination
    2. Axillary temperature > 37.0 °C

Sites / Locations

  • Shangyu District Center for Disease Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

EV71 vaccine & blood sampling (0, 10,60)

EV71 vaccine & blood sampling (0, 20,60)

EV71 vaccine& blood sampling (0, 30, 60)

Arm Description

This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.

This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.

This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.

Outcomes

Primary Outcome Measures

The seroconversion rate of EV71 neutralizing antibody 30 days after the two doses vaccination
Immunogenicity indicator

Secondary Outcome Measures

The seroconversion rate of EV71 neutralizing antibody 10, 20 and 30 days after the first dose vaccination
Immunogenicity indicator
The seropositive rate of EV71 neutralizing antibody 10, 20, 30, and 60 days after the first dose vaccination
Immunogenicity indicator
GMT and GMT increase fold of EV71 neutralizing antibody 10,20,30,and 60 days after the first dose vaccination
Immunogenicity indicator
Incidence of unsolicited local or systemic adverse events within 3 days after each dose
Safety indicator
Incidence of unsolicited adverse events within 30 days after each dose
Safety indicator
Incidence of the serious adverse events within 60 days after the first dose vaccination
Safety indicator

Full Information

First Posted
September 7, 2017
Last Updated
December 28, 2018
Sponsor
Sinovac Biotech Co., Ltd
Collaborators
Zhejiang Provincial Center for Disease Control and Prevention, Shangyu District Center for Disease Control and Prevention
search

1. Study Identification

Unique Protocol Identification Number
NCT03278132
Brief Title
Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine
Official Title
A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
July 16, 2017 (Actual)
Primary Completion Date
September 15, 2017 (Actual)
Study Completion Date
September 15, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sinovac Biotech Co., Ltd
Collaborators
Zhejiang Provincial Center for Disease Control and Prevention, Shangyu District Center for Disease Control and Prevention

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different time after vaccination
Detailed Description
This study is an open-labelled, single-centered, stratified-randomized, phase IV clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine (developed by Sinovac Biotech Co., Ltd.) in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different times after vaccination. The enrolled subjects in this study receive two doses of EV71 vaccine with 1-month interval between doses. To evaluate safety of the vaccine, subjects will be observed for 30 days after the injection for the potential adverse events. To evaluate the immunogenicity of the vaccine, venous blood will be collected for the neutralizing antibody detection prior to vaccination, 10/20/30 days after the 1st dose and 30 days after the 2nd dose vaccination. All subjects will receive blood sampling for three times. Subjects will be randomly assigned to receive blood sampling at 10/20/30 days after 1st dose injection, with a ratio of 1: 1: 1.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hand, Foot and Mouth Disease
Keywords
Inactivated Enterovirus Type 71 (EV71) Vaccine, Safety, Immunogenicity, Infant

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EV71 vaccine & blood sampling (0, 10,60)
Arm Type
Experimental
Arm Description
This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
Arm Title
EV71 vaccine & blood sampling (0, 20,60)
Arm Type
Experimental
Arm Description
This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
Arm Title
EV71 vaccine& blood sampling (0, 30, 60)
Arm Type
Experimental
Arm Description
This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
Intervention Type
Biological
Intervention Name(s)
EV71 vaccine
Intervention Description
Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
Primary Outcome Measure Information:
Title
The seroconversion rate of EV71 neutralizing antibody 30 days after the two doses vaccination
Description
Immunogenicity indicator
Time Frame
30 days
Secondary Outcome Measure Information:
Title
The seroconversion rate of EV71 neutralizing antibody 10, 20 and 30 days after the first dose vaccination
Description
Immunogenicity indicator
Time Frame
10,20,and 30 days
Title
The seropositive rate of EV71 neutralizing antibody 10, 20, 30, and 60 days after the first dose vaccination
Description
Immunogenicity indicator
Time Frame
10, 20,30,and 60 days
Title
GMT and GMT increase fold of EV71 neutralizing antibody 10,20,30,and 60 days after the first dose vaccination
Description
Immunogenicity indicator
Time Frame
10,20,30,and 60 days
Title
Incidence of unsolicited local or systemic adverse events within 3 days after each dose
Description
Safety indicator
Time Frame
3 days
Title
Incidence of unsolicited adverse events within 30 days after each dose
Description
Safety indicator
Time Frame
30 days
Title
Incidence of the serious adverse events within 60 days after the first dose vaccination
Description
Safety indicator
Time Frame
60 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
35 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy volunteers aged 6-35 months old Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study Proven legal identity Exclusion Criteria: For subjects with any of the following conditions, vaccination should not be administrated: History of hand foot and mouth disease Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, pain, etc Severe chronic diseases Thrombocytopenia or hemorrhagic disease Immunodeficiency disease or receipt of immunosuppressant treatment Uncontrolled epilepsy or progressive neurological disorders(e.g. Guillain-Barre syndrome) Acute disease or acute stage of chronic disease prior to the study entry History of thyroidectomy, thyroid disease within 12 months prior to the study entry Asplenia or functional asplenia Axillary temperature >37.0 ℃ Any other factor that suggesting the volunteer is unsuitable for this study based on the judgment of investigators Exclusion Criteria of the Second Injection: Subjects with any of the following conditions are forbidden to continue the 2nd dose of vaccination: Any serious adverse event that has a causal relationship with the investigated vaccine Severe allergic reactions or hypersensitivity after vaccination (including urticaria / rash appear within 30 minutes after vaccination Any confirmed or suspected autoimmune disease or immunodeficiency disease (e.g., HIV infection) Other reactions (including severe pain, severe swelling, severe activity limitation, persistent hyperthermia, severe headache or other systemic or local reactions)determined by the investigators For subjects suffering from acute disease or acute stage of chronic disease , whether to continue vaccination depends on themselves Subjects with the following conditions may receive vaccination in delayed time or withdraw from the study depending on the judgment of investigator Acute disease (moderate or severe disease with or without fever) in case of vaccination Axillary temperature > 37.0 °C
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Huakun Lv
Organizational Affiliation
Zhejiang Provincial Center for Disease Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shangyu District Center for Disease Control and Prevention
City
Shaoxing
State/Province
Zhejiang
ZIP/Postal Code
312300
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
31977278
Citation
Wang S, Zeng J, Zhang X, Gan Z, Fan J, Chen Y, Liang Z, Hu X, Zeng G, Lv H. Short-term dynamic changes in neutralizing antibodies against enterovirus 71 after vaccination. Hum Vaccin Immunother. 2020 Jul 2;16(7):1595-1601. doi: 10.1080/21645515.2020.1711678. Epub 2020 Jan 24.
Results Reference
derived

Learn more about this trial

Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

We'll reach out to this number within 24 hrs